Background: Screening of natural compounds for the development of anti-acne therapeutic agents has been steadily required considering various side effects of acne medications. However, previous studies have mainly focused on experimental tests without clinical trials and histopathological analysis. Objectives: To compare the clinical efficacy, safety and histopathological changes between Lactobacillus-fermented Chamaecyparis obtusa (LFCO) and existing tea tree oil (TTO). Methods: A total of 34 patients were instructed to apply 5% LFCO to the involved areas of a randomly allocated side and 5% TTO extract to the other side for 8 weeks in a double-blind split-face clinical trial. Results: After 8 weeks, inflammatory acne lesions were reduced by 65.3% on the LFCO side and by 38.2% on the TTO side. LFCO was also superior to TTO in the onset time of efficacy (p < 0.05). The LFCO side further demonstrated improvement for non-inflammatory lesions (52.6%, p < 0.05), decreased size of sebaceous glands and sebum output reductions. Patients' subjective satisfaction was also higher without severe adverse reactions. Protein expressions of nuclear factor κB decreased earlier on the LFCO side, and those of interleukin-1a (IL-1a), IL-8, insulin-like growth factor 1 receptor and sterol regulatory element-binding protein 1 decreased subsequently. Ultra-performance liquid chromatography/high-resolution mass spectrometry further demonstrated that the contents of dihydroxybenzoic acid, taxifolin and quercetin were increased in LFCO after fermentation. Conclusions: LFCO treatment was rapid and effective for treating acne lesions compared to TTO. Histopathological findings correlated well with the clinical acne grade and treatment response. This novel natural compound appears to be effective and safe for acne treatment.

Keywords:
Acne, Therapeutics, Natural products, Chamaecyparis obtusa, Tea tree oil
1.
James WD: Clinical practice. Acne. N Engl J Med 2005;352:1463-1472.
2.
Williams HC, Dellavalle RP, Garner S: Acne vulgaris. Lancet 2012;379:361-372.
3.
Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D; Global Alliance to Improve Outcomes in Acne: Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49(suppl 1):S1-S37.
4.
Hayashi N, Kawashima M: Multicenter randomized controlled trial on combination therapy with 0.1% adapalene gel and oral antibiotics for acne vulgaris: comparison of the efficacy of adapalene gel alone and in combination with oral faropenem. J Dermatol 2012;39:511-515.
5.
Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, Thiboutot DM, Van Voorhees AS, Beutner KA, Sieck CK, Bhushan R; American Academy of Dermatology/American Academy of Dermatology Association: Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:651-663.
6.
Jain A, Basal E: Inhibition of Propionibacterium acnes-induced mediators of inflammation by Indian herbs. Phytomedicine 2003;10:34-38.
7.
Nam C, Kim S, Sim Y, Chang I: Anti-acne effects of Oriental herb extracts: a novel screening method to select anti-acne agents. Skin Pharmacol Appl Skin Physiol 2003;16:84-90.
8.
Pazyar N, Yaghoobi R, Bagherani N, Kazerouni A: A review of applications of tea tree oil in dermatology. Int J Dermatol 2013;52:784-790.
9.
Enshaieh S, Jooya A, Siadat AH, Iraji F: The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: a randomized, double-blind placebo-controlled study. Indian J Dermatol Venereol Leprol 2007;73:22-25.
10.
Blackwood B, Thompson G, McMullan R, Stevenson M, Riley TV, Alderdice FA, Trinder TJ, Lavery GG, McAuley DF: Tea tree oil (5%) body wash versus standard care (Johnson's Baby Softwash) to prevent colonization with methicillin-resistant Staphylococcus aureus in critically ill adults: a randomized controlled trial. J Antimicrob Chemother 2013;68:1193-1199.
11.
Bassett IB, Pannowitz DL, Barnetson RS: A comparative study of tea-tree oil versus benzoyl peroxide in the treatment of acne. Med J Aust 1990;153:455-458.
12.
Joo SS, Yoo YM, Ko SH, Choi W, Park MJ, Kang HY, Choi KC, Choi IG, Jeung EB: Effects of essential oil from Chamaecyparis obtusa on the development of atopic dermatitis-like skin lesions and the suppression of Th cytokines. J Dermatol Sci 2010;60:122-125.
13.
Baba T, Nakano H, Tamai K, Sawamura D, Hanada K, Hashimoto I, Arima Y: Inhibitory effect of beta-thujaplicin on ultraviolet B-induced apoptosis in mouse keratinocytes. J Invest Dermatol 1998;110:24-28.
14.
Hong EJ, Na KJ, Choi IG, Choi KC, Jeung EB: Antibacterial and antifungal effects of essential oils from coniferous trees. Biol Pharm Bull 2004;27:863-866.
15.
Koyama S, Yamaguchi Y, Tanaka S, Motoyoshiya J: A new substance (Yoshixol) with an interesting antibiotic mechanism from wood oil of Japanese traditional tree (Kiso-Hinoki), Chamaecyparis obtusa. Gen Pharmacol 1997;28:797-804.
16.
Jappe U, Ingham E, Henwood J, Holland KT: Propionibacterium acnes and inflammation in acne; P. acnes has T-cell mitogenic activity. Br J Dermatol 2002;146:202-209.
17.
Pierard GE, Ries G, Cauwenbergh G: New insight into the topical management of excessive sebum flow at the skin surface. Dermatology 1998;196:126-129.
18.
Nouveau-Richard S, Zhu W, Li YH, Zhang YZ, Yang FZ, Lian S, Qian BY, Ran YP, Bouillon C, Chen HD, de Lacharrière O: Oily skin: specific features in Chinese women. Skin Res Technol 2007;13:43-48.
19.
Nagy I, Pivarcsi A, Koreck A, Szell M, Urban E, Kemeny L: Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol 2005;124:931-938.
20.
Nagy I, Pivarcsi A, Kis K, Koreck A, Bodai L, McDowell A, Seltmann H, Patrick S, Zouboulis CC, Kemény L: Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect 2006;8:2195-2205.
21.
Kwon HH, Yoon JY, Park SY, Suh DH: Analysis of distribution patterns of Propionibacterium acnes phylotypes and Peptostreptococcus species from acne lesions. Br J Dermatol 2013;169:1152-1155.
22.
Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, Thiboutot DM: Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012;132:2198-2205.
23.
Jalian HR, Liu PT, Kanchanapoomi M, Phan JN, Legaspi AJ, Kim J: All-trans retinoic acid shifts Propionibacterium acnes-induced matrix degradation expression profile toward matrix preservation in human monocytes. J Invest Dermatol 2008;128:2777-2782.
24.
Kang S, Cho S, Chung JH, Hammerberg C, Fisher GJ, Voorhees JJ: Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappa B and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol 2005;166:1691-1699.
25.
Smith TM, Cong Z, Gilliland KL, Clawson GA, Thiboutot DM: Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol 2006;126:1226-1232.
26.
Smith TM, Gilliland KL, Clawson GA, Thiboutot D: IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008;128:1286-1293.
27.
Isard O, Knol AC, Ariès MF, Nguyen JM, Khammari A, Castex-Rizzi N, Dréno B: Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis and induces keratinocyte proliferation. J Invest Dermatol 2011;131:59-66.
28.
Kwon HH, Lee JB, Yoon JY, Park SY, Ryu HH, Park BM, Kim YJ, Suh DH: The clinical and histological effect of home-use, combination blue-red LED phototherapy for mild-to-moderate acne vulgaris in Korean patients: a double-blind, randomized controlled trial. Br J Dermatol 2013;168:1088-1094.
29.
Anhê GF, Okamoto MM, Kinote A, Sollon C, Lellis-Santos C, Anhê FF, Lima GA, Hirabara SM, Velloso LA, Bordin S, Machado UF: Quercetin decreases inflammatory response and increases insulin action in skeletal muscle of ob/ob mice and in L6 myotubes. Eur J Pharmacol 2012;689:285-293.
30.
Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV: Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 2005;280:5636-5645.
31.
Yang JK, Choi MS, Seo WT, Rinker DL, Han SW, Cheong GW: Chemical composition and antimicrobial activity of Chamaecyparis obtusa leaf essential oil. Fitoterapia 2007;78:149-152.
32.
Tian M, Bi W, Row KH: Simultaneous extraction and separation of flavonols and flavones from Chamaecyparis obtusa by multi-phase extraction using an ionic liquid-modified microsphere polymer. Phytochem Anal 2012;23:576-581.
33.
Arima Y, Nakai Y, Hayakawa R, Nishino T: Antibacterial effect of beta-thujaplicin on staphylococci isolated from atopic dermatitis: relationship between changes in the number of viable bacterial cells and clinical improvement in an eczematous lesion of atopic dermatitis. J Antimicrob Chemother 2003;51:113-122.
34.
Lee GS, Hong EJ, Gwak KS, Park MJ, Choi KC, Choi IG, Jang JW, Jeung EB: The essential oils of Chamaecyparis obtusa promote hair growth through the induction of vascular endothelial growth factor gene. Fitoterapia 2010;81:17-24.
35.
Lu J, Papp LV, Fang J, Rodriquez-Neito S, Zhivotovsky B, Holmgren A: Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 2006;66:4410-4418.
36.
Amadou I, Le GW, Shi YH, Sakagbadamosi O, Tabitakamara M, Jin S: Optimized Lactobacillus plantarum Lp6 solid-state fermentation and proteolytic hydrolysis improve some nutritional attributes of soybean protein meal. J Food Biochem 2011;35:1686-1694.
37.
Yang EJ, Kim SI, Park SY, Bang HY, Jeong JH, So JH, Rhee IK, Song KS: Fermentation enhances the in vitro antioxidative effect of onion (Allium cepa) via an increase in quercetin content. Food Chem Toxicol 2012;50:2042-2048.
38.
Lim YH, Kim IH, Seo JJ: In vitro activity of kaempferol isolated from the Impatiens balsamina alone and in combination with erythromycin or clindamycin against Propionibacterium acnes. J Microbiol 2007;45:473-477.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.